News & Updates

Show Multimedia Only
Post-treatment HBsAg loss greater with TDF vs entecavir

Post-treatment HBsAg loss greater with TDF vs entecavir

12 Jun 2023

In patients with chronic hepatitis B (CHB) without cirrhosis, the rates of hepatitis B surface antigen (HBsAg) loss appear to be higher after discontinuation of tenofovir disoproxil fumarate (TDF) than of entecavir, and this is particularly true for patients who have not experienced relapse after treatment discontinuation, according to a study.

Post-treatment HBsAg loss greater with TDF vs entecavir

12 Jun 2023
Progression-free on immunotherapy for NSCLC? Stopping treatment at 2 years may be OK

Progression-free on immunotherapy for NSCLC? Stopping treatment at 2 years may be OK

12 Jun 2023 byJairia Dela Cruz

For patients with advanced nonsmall cell lung cancer (NSCLC) who remain progression-free on immune checkpoint inhibitor (ICI)-based therapy at 2 years, continuing treatment does not appear to confer any survival advantage as opposed to stopping, according to a retrospective study presented at ASCO 2023.

Progression-free on immunotherapy for NSCLC? Stopping treatment at 2 years may be OK

12 Jun 2023
Migraine status helps improve CVD risk prediction

Migraine status helps improve CVD risk prediction

12 Jun 2023

The addition of information on migraine with aura (MA) status to the cardiovascular disease (CVD) risk prediction algorithms results in a better model fit but falls short of substantially improving risk stratification among women, according to a study.

Migraine status helps improve CVD risk prediction

12 Jun 2023
Perioperative durvalumab-based regimen improves outcomes in resectable NSCLC

Perioperative durvalumab-based regimen improves outcomes in resectable NSCLC

12 Jun 2023 byAudrey Abella

In individuals with resectable non-small-cell lung cancer (NSCLC), the addition of perioperative durvalumab to neoadjuvant chemotherapy improved pathologic complete response (pCR) and event-free survival (EFS), findings from the AEGEAN study have shown.

Perioperative durvalumab-based regimen improves outcomes in resectable NSCLC

12 Jun 2023
Add-on myoinositol helps with menstrual period regularity in women with PCOS

Add-on myoinositol helps with menstrual period regularity in women with PCOS

12 Jun 2023

In the treatment of women with polycystic ovary syndrome (PCOS), adding myoinositol to metformin provides further benefits for improving the regularity of menstrual cycle, with subsequent gains in quality of life, according to a study.

Add-on myoinositol helps with menstrual period regularity in women with PCOS

12 Jun 2023
Flavonoid intake improves survival after CRC diagnosis

Flavonoid intake improves survival after CRC diagnosis

11 Jun 2023

Patients who have been diagnosed with colorectal cancer (CRC) may benefit from increased flavonoid intake, which has been shown to reduce CRC-specific mortality in a recent study.

Flavonoid intake improves survival after CRC diagnosis

11 Jun 2023
Upfront osimertinib matches sequential treatment for prolonging survival in EGFR-mutant NSCLC

Upfront osimertinib matches sequential treatment for prolonging survival in EGFR-mutant NSCLC

10 Jun 2023 byJairia Dela Cruz

Patients with nonsmall cell lung cancer (NSCLC) harbouring EGFR mutation appear to experience similar survival outcomes with either frontline osimertinib therapy or sequential treatment approach of gefitinib followed by osimertinib, although upfront osimertinib leads to a significant reduction in the risk of brain progression, as shown in the results of the APPLE trial presented at ELCC 2023.

Upfront osimertinib matches sequential treatment for prolonging survival in EGFR-mutant NSCLC

10 Jun 2023
Omega-3 fatty acids lower risk of dementia, cognitive decline

Omega-3 fatty acids lower risk of dementia, cognitive decline

10 Jun 2023
NAFLD a risk factor for young-onset hypertension

NAFLD a risk factor for young-onset hypertension

09 Jun 2023

Young people with nonalcoholic fatty liver disease (NAFLD) are at increased risk of hypertension, especially women and those with more severe hepatic steatosis, as shown in a study.

NAFLD a risk factor for young-onset hypertension

09 Jun 2023